Access Restriction

Author Infections, B.
Source CiteSeerX
Content type Text
File Format PDF
Subject Domain (in DDC) Computer science, information & general works ♦ Data processing & computer science
Abstract Prophylaxis- The drug has been shown to reduce the incidence of laboratory-confirmed influenza, compared to placebo when given as 75mg once or twice daily prophylactically for six weeks during periods of local influenza activity. However evidence for its use as post-exposure prophylaxis in “at-risk ” patients is restricted to one study of 955 household contacts of 377 influenza index cases, but which did not differentiate the “at-risk” population from the other contacts, and another of 548 elderly subjects in a nursing home. Treatment- Four studies (two published in abstract form) have shown oseltamivir, at doses of 75 or 150mg twice daily for five days, started within 36 hours of symptom onset in naturally acquired influenza, reduced the duration of illness by 1.3-1.8 days and illness severity by up to 38%. However there is a very limited database to assess the impact of treatment in high-risk individuals such as the elderly, those with chronic cardiac or respiratory disease or children aged 1 to 12 years. No data are currently available on outcomes such as complication and hospitalisation rates, or relative efficacy with alternative antiviral treatments, or on the drug’s incremental efficacy in those who have been immunised. As with all new drugs, it is not possible to assess the full safety profile from current trial data, but oseltamivir appears well tolerated. Nausea and vomiting are the most frequently observed adverse effects and may occur in up to 10 % of treated patients.
Educational Role Student ♦ Teacher
Age Range above 22 year
Educational Use Research
Education Level UG and PG ♦ Career/Technical Study